About
VALANX develops optimized protein-drug conjugation technology called GoldenSite™ to enable site-specific, fast, and cost-effective protein conjugation for next-generation therapies, aiming to improve drug safety and efficacy particularly in antibody-drug conjugates.
Explore VALANX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.